Zydus
dedicated to life

Cadila
Healthcare Limited

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

PR/CA/2011
June 17, 2011

Bombay Stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001 Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051 Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015 Fax No. 079 - 26308877

Re.: Press Release.

Dear Sir,

We are pleased to inform that Zydus's US subsidiary Company enters into an Asset Purchase Agreement in US to acquire assets of the US based Pharmaceutical Company.

Please find attached herewith the press release proposed to be issued in the matter, which provides more details and is self-explanatory.

This is for the information of the members of the Exchange and public at large.

Thanking you

Yours faithfully
FOR **CADILA HEALTHCARE LIMITED**

UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above.

Zydus' US subsidiary enters into an asset purchase agreement in the US

Ahmedabad, June 17, 2011

Zydus Pharmaceuticals USA Inc., through its subsidiary Zynesher Pharmaceuticals USA LLC has entered into an agreement to acquire the assets of the US based pharmaceutical company Nesher Pharmaceuticals Inc. Nesher operates as the generic subsidiary of KV Pharmaceutical,based at St. Louis, Missouri, USA. The financial details of the agreement are undisclosed.

Nesher has considerable expertise in niche therapies which have development or production barriers, such as controlled release medications or DEA-controlled substances. The broad-based assets purchase agreement includes assets and assumption of certain liabilities, Nesher's existing and pipeline ANDAs, certain manufacturing facilities and a full fledged research and development lab. With this, Zydus will now be able to manufacture and distribute generic controlled substances in the US market, which otherwise cannot be imported.The market for controlled substances medications in the US is estimated at $7 bn.

Speaking on the development, Chairman and Managing Director of Zydus Cadila, Mr. Pankaj R. Patel said, "We have always looked at value-accruing opportunities and we believe that this new development gives us access to a difficult-to-develop product pipeline, expertise and infrastructure that will add value to our operations in the US. It also presents the right fit as it helps us strengthen our generic operations in the US with technology-distinguished specialty generics."

The acquired ANDA pipeline comprising 8 existing filings and 5 products under development present a tremendous market potential as they belong to high growth, niche segments which have a combined estimated market size of over $ 2.1 bn.

The agreement also encompasses supply and technical services agreements by which certain products of KV Pharmaceutical will be manufactured by Zynesher Pharmaceuticals USA LLC.

***

For further information please contact :
The Corporate Communications Department

'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines) Fax : +91-79-2686 2365/66 www.zyduscadila.com